PT-141 (Bremelanotide) Sexual Health Therapy in New York City

Bremelanotide — the pharmaceutical name for PT-141 — is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. That regulatory approval validates both the mechanism and the safety profile in a way that matters when evaluating sexual health treatments, where the spectrum of claims is wide and the evidentiary quality varies enormously. For men, PT-141 is used off-label, which is standard for many pharmacologically established compounds where the mechanism is well-understood and clinical experience is substantial. At TRT New York, every prescription follows a comprehensive sexual health evaluation — not a form submission, a physician consultation.

Sildenafil (Viagra) and tadalafil (Cialis) are PDE5 inhibitors — they work by relaxing smooth muscle and increasing blood flow to genital tissue. They address the hydraulics of sexual function but don't touch desire or motivation. That's why they're effective for some presentations and not others: if the issue is blood flow, they help. If the issue is that sexual desire isn't there to begin with — which is the actual complaint for most patients seeking PT-141 — they don't solve the problem. PT-141 operates in the brain through melanocortin receptors that regulate desire and arousal centrally. That neurological mechanism is what makes it effective for cases where PDE5 inhibitors have already been tried and found insufficient, or where desire rather than mechanics is the presenting concern.

Onset is typically 45 to 90 minutes after injection. The duration of effect is generally 6–12 hours, though patients vary. The practical protocol recommendation is to administer approximately 1–2 hours before anticipated sexual activity — enough time for full onset without the window being too wide. Unlike medications where the timing is forgiving, PT-141's central mechanism means the optimal window for effect is real. Your TRT New York physician will walk through timing specifics and what to expect on the first use before any prescription is finalized.

The most commonly reported side effects are nausea and flushing, both of which are dose-dependent and typically resolve within 1–2 hours. The standard approach is to start at a lower dose and titrate upward based on response — which substantially reduces the likelihood of these effects being disruptive. Our physicians review the complete profile with patients before any prescription is written, including what to monitor and when to reach out.

Yes — and PT-141 is one of the few sexual health pharmacologics with FDA approval specifically for women, as Vyleesi for hypoactive sexual desire disorder. The central mechanism, activating melanocortin receptors that govern arousal and desire in the brain, is equally relevant for female patients dealing with low libido, HSDD, or postmenopausal changes in sexual function. We evaluate female patients for PT-141 through the same comprehensive sexual health assessment used for all patients.

PT-141 enhances the brain's sensitivity to sexual stimulation and increases intrinsic desire — it does not produce arousal without context. Most patients describe an increased responsiveness to sexual cues and an enhanced sense of desire rather than spontaneous physical arousal occurring in isolation.

Schedule a consultation at TRT New York, 120 Broadway, New York, NY 10271, or call (332) 237-6820. PT-141 evaluations involve a complete sexual health assessment — not a quick prescription. Your physician reviews your full medical history, current medications, hormonal status, and the specific nature of the issue before determining whether PT-141 is appropriate and at what dose. We serve patients from Manhattan, Brooklyn, Queens, The Bronx, Staten Island, Westchester, and Long Island, with telemedicine follow-up available once the initial protocol is established.